Bayer Partners With Population Health Research Institute (PHRI) On Global Clinical Research Evaluating COVID-19 Treatments
Bayer announced today its Canadian organization Bayer Inc., Mississauga, Ontario, will partner with the Population Health Research Institute (PHRI) in launching a major clinical research program aimed at identifying potential treatments against COVID-19. The two studies will evaluate the safety and efficacy of different combination therapies including Bayer's chloroquine and interferon beta-1b.
"Treatments against COVID-19 are urgently needed as no validated options are currently available," said Dr. Mike Devoy, Member of the Executive Committee of Bayer AG's Pharmaceuticals Division and Chief Medical Officer. "We want to contribute to the global fight against the coronavirus through our products and expertise and look forward to partnering with the PHRI."
Bayer will make a financial commitment of CAD 1.5 million (approx. 1 million euros) towards the studies and will supply study drugs to support the research. This adds to the CAD 0.5 million committed by the PHRI earlier this month which enabled the development of the research program.
"Specifically, an outpatient study will evaluate the combination of chloroquine with azithromycin to see if this treatment can prevent deterioration leading to hospital admission, while a second study will evaluate the combination of chloroquine with azithromycin, as well as interferon beta-1b, to prevent admission to intensive care, mechanical ventilation and/or death to combat COVID-19," said Salim Yusuf, Executive Director of PHRI. "Our goal is to assess the value of these and other therapies rapidly so that the results can inform practice as soon as possible."